Disease map-based biomarker selection and pre-validation for bladder cancer diagnostic

References

• Babjuk M, Oosterlinck W, Sylvester R, et al. (2011). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59:997–1008
   PubMed Web of Science ®Google Scholar
• Bettum IJ, Vasiliauskaite K, Nygaard V, et al. (2014). Metastasis-associated protein S100A4 induces a network of inflammatory cytokines that activate stromal cells to acquire pro-tumorigenic properties. Cancer Lett 344:28–39
   PubMed Web of Science ®Google Scholar
• Budman LI, Kassouf W, Steinberg JR. (2008). Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J 2:212–21
   PubMed Web of Science ®Google Scholar
• Clark PE, Agarwal N, Biagioli MC, et al. (2013). Bladder cancer. J Natl Compr Cancer Netw 11:446–75
   PubMed Web of Science ®Google Scholar
• Donmez G, Sullu Y, Baris S, et al. (2009). Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas. Pathol Res Pract 205:854–7
   PubMed Web of Science ®Google Scholar
• Fechete R, Heinzel A, Söllner J, et al. (2013). Using information content for expanding human protein coding gene interaction. Networks J Comput Sci Syst Biol 6:073--082
   Google Scholar
• Ferlay J, Soerjomataram I, Ervik M, et al. (2013). GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Available from: http://globocan.iarc.fr/ [last accessed 12 Nov 2014]
   Google Scholar
• Gee J, Lee I-L, Grossman HB, Sabichi AL. (2008). Forced COX-2 expression induces PGE(2) and invasion in immortalized urothelial cells. Urol Oncol 26:641–5
   PubMed Web of Science ®Google Scholar
• Hall MC, Chang SS, Dalbagni G, et al. (2007). Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178:2314–30
   PubMed Web of Science ®Google Scholar
• Heinzel A, Mühlberger I, Fechete R, et al. (2014). Functional molecular units for guiding biomarker panel design. Methods Mol Biol 1159:109–33
   PubMedGoogle Scholar
• Inoue K, Slaton JW, Kim SJ, et al. (2000). Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res 60:2290–9
   PubMed Web of Science ®Google Scholar
• Kader AK, Liu J, Shao L, et al. (2007). Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin Cancer Res 13:2614–20
   PubMed Web of Science ®Google Scholar
• Konety BR, Nguyen T-ST, Dhir R, et al. (2000). Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res 6:2618–25
   PubMed Web of Science ®Google Scholar
• Kopparapu PK, Boorjian SA, Robinson BD, et al. (2013). Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res 33:2381–90
   PubMed Web of Science ®Google Scholar
• Margulis V, Shariat SF, Ashfaq R, et al. (2007). Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. J Urol 177:1163–8
   PubMed Web of Science ®Google Scholar
• Morgan R, Bryan RT, Javed S, et al. (2013). Expression of engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarker. Eur J Cancer 49:2214–22
   PubMed Web of Science ®Google Scholar
• Nakanishi R, Oka N, Nakatsuji H, et al. (2009). Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer. Urol Int 83:98–106
   PubMed Web of Science ®Google Scholar
• Pei J, Lou Y, Zhong R, Han B. (2014). MMP9 activation triggered by epidermal growth factor induced FoxO1 nuclear exclusion in non-small cell lung cancer. Tumour Biol 35:6673–8
   PubMed Web of Science ®Google Scholar
• Ramachandran N, Srivastava S, LaBaer J. (2008). Applications of protein microarrays for biomarker discovery. Proteom Clin Appl 2:1444–59
   PubMed Web of Science ®Google Scholar
• Robin X, Turck N, Hainard A, et al. (2013). PanelomiX: a threshold-based algorithm to create panels of biomarkers. Transl Proteom 1:57–64
   Google Scholar
• Sanchez-Carbayo M, Socci ND, Lozano J, et al. (2006). Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24:778–89
   PubMed Web of Science ®Google Scholar
• Shariat SF, Karakiewicz PI, Godoy G, et al. (2009). Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res 15:7012–19
   PubMed Web of Science ®Google Scholar
• Shariat SF, Karam JA, Lotan Y, Karakiewizc PI. (2008). Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol 10:120–35
   PubMedGoogle Scholar
• Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. (2006). Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466–5 (discussion 475–7)
   PubMed Web of Science ®Google Scholar
• Thomas CE, Sexton W, Benson K, et al. (2010). Urine collection and processing for protein biomarker discovery and quantification. Cancer Epidemiol Biomark Prev 19:953–9
   PubMed Web of Science ®Google Scholar
• Urquidi V, Kim J, Chang M, et al. (2012). CCL18 in a multiplex urine-based assay for the detection of bladder cancer. PLoS One 7:e37797
   PubMed Web of Science ®Google Scholar
• Van Rhijn BWG, van der Poel HG, van der Kwast TH. (2005). Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 47:736–48
   PubMed Web of Science ®Google Scholar
• Van Tilborg AA, Bangma CH, Zwarthoff EC. (2009). Bladder cancer biomarkers and their role in surveillance and screening. Int J Urol 16:23–30
   PubMed Web of Science ®Google Scholar
• Vrooman OPJ, Witjes JA. (2008). Urinary markers in bladder cancer. Eur Urol 53:909–16
   PubMed Web of Science ®Google Scholar